Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and other comparators in patients with type 2 diabetes and obesity.
Tirzepatide is a dual-acting hormone medication (GIP/GLP-1) that offers even greater weight loss than semaglutide (up to 21% in trials). It is administered as a once-weekly injection, starting at a low dose and increasing every 4 weeks. It is particularly effective for patients with type 2 diabetes and obesity, improving both blood sugar and weight significantly more than other comparators.
Across the SURPASS phase 3 programme versus placebo and active comparators, including semaglutide, tirzepatide has shown superior dose-dependent reductions in HbA1c levels up to 2.5% and body weight up to 13%, compared with all comparators [88-91].
Why this rating
Supported by Phase III trials (SURPASS, SURMOUNT) comparing directly to other drugs.
Source
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son et al. · Endocrinology and Metabolism · 2024
DOI 10.3803/enm.2024.1940
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide produce significant weight loss and improve cardiovascular outcomes by acting as incretin mimetics that target G-protein-coupled receptors to regulate body fat and energy balance.Strong
- GLP-1 receptor agonists provide cardiovascular protection by reducing major adverse cardiac events (MACE), independent of substantial glucose lowering, through mechanisms including improved endothelial function and reduced inflammation.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →